THERAPY DOSSIER · th-661405f8a7ba

Embryonic stem cell-derived progenitor motor neurons in fibrin scaffolds with sustained delivery of neurotrophic growth factors and anti-inhibitory molecules (chondroitinase ABC, NEP1-40)

Biologic

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 26384702 ↗2015Mixed findings

Combination therapy of stem cell derived neural progenitors and drug delivery of anti-inhibitory molecules for spinal cord injury.

RatSpinal cord injuryUnspecifiedTransplantation into the injury siteSub-acute stage after injury

Model: Sub-acute spinal cord injury with fibrin scaffold transplantation

Scaffolds containing progenitor motor neurons without anti-inhibitory molecules showed cell survival, neuronal differentiation, axonal extension and integration with host tissue, but combining progenitor motor neurons with sustained delivery of anti-inhibitory molecules reduced cell survival and in…

Extraction: extract · Supplied extraction confidence: 0.55. Machine-extracted fields require source verification.

Loading the evidence…